{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:37:09Z","timestamp":1758962229584,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tiansheng Taifeng Pharm","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Generalized anxiety disorder (GAD) is a persistent and common mental disorder that entails significant impairments in role functioning and quality of life. Currently available effective interventions include psychological therapies, self-help approaches, and pharmacological treatments, which do not quite meet clinical needs, and the ideal anxiolytic is still being sought. Shu-gan-qing-re (SGQR) formula, a Chinese patent medicine, has been well received by patients with GAD in Chinese clinical practice for years. The present prospective, double-blind, double-dummy, randomized controlled trial is designed to investigate the efficacy and safety of SGQR formula for GAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>A total of 200 eligible participants will be recruited from four hospitals in different parts of China. They will be randomly assigned to either the study group or the control group in a ratio of 1:1. Participants allocated to the study group will receive SGQR formula and buspirone placebo, while buspirone and SGQR placebo will be applied in the control group. Six scheduled visits will be conducted over the course of 8\u2009weeks. Outcome measurements include Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-17 (HAMD-17), Clinical Global Impression-Improvement Scale (CGI-I), Traditional Chinese Medicine Syndrome Scale for GAD, and pro-inflammatory cytokine tests: interleukin-1 beta (IL-1\u03b2), IL-6, and tumor necrosis factor-alpha. Adverse reactions will be evaluated by using the Treatment Emergent Symptom Scale\u00a0(TESS). Safety outcomes and adverse events will also be recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The study will provide scientific and objective assessments for the efficacy and safety of SGQR formula for patients with GAD, hopefully offering clinicians an alternative approach to GAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry, ID: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=21902\">ChiCTR-IPR-17013058<\/jats:ext-link>. Registered on October 20, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-020-4186-6","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T09:02:57Z","timestamp":1584176577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-1031","authenticated-orcid":false,"given":"Pei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhe","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"issue":"9553","key":"4186_CR1","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/S0140-6736(06)69865-6","volume":"368","author":"P Tyrer","year":"2006","unstructured":"Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156\u201366.","journal-title":"Lancet"},{"issue":"3","key":"4186_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","volume":"6","author":"Y Huang","year":"2019","unstructured":"Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211\u201324.","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"4186_CR3","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1017\/S0033291713002997","volume":"44","author":"M Burstein","year":"2014","unstructured":"Burstein M, Beesdo-Baum K, He JP, Merikangas KR. Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic, and clinical characteristics. Psychol Med. 2014;44(11):2351\u201362.","journal-title":"Psychol Med"},{"issue":"9","key":"4186_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, J\u00f6nsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"4186_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/da.20257","volume":"25","author":"DL Hoffman","year":"2008","unstructured":"Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72\u201390.","journal-title":"Depress Anxiety"},{"issue":"11","key":"4186_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2165\/00003495-200262110-00005","volume":"62","author":"JJ Sramek","year":"2002","unstructured":"Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder: treatment options. Drugs. 2002;62(11):1635\u201348.","journal-title":"Drugs"},{"issue":"7","key":"4186_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/occmed\/kqv054","volume":"65","author":"E Thompson","year":"2015","unstructured":"Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601.","journal-title":"Occup Med (Lond)"},{"key":"4186_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2017.05.014","volume":"93","author":"M Zimmerman","year":"2017","unstructured":"Zimmerman M, Martin J, Clark H, McGonigal P, Harris L, Holst CG, et al. Measuring anxiety in depressed patients: A comparison of the Hamilton anxiety rating scale and the DSM-5 Anxious Distress Specifier Interview. J Psychiatr Res. 2017;93:59\u201363.","journal-title":"J Psychiatr Res"},{"key":"4186_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.clinpsy.3.022806.091444","volume":"3","author":"RC Kessler","year":"2007","unstructured":"Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol. 2007;3:137\u201358.","journal-title":"Annu Rev Clin Psychol"},{"issue":"2\u20133","key":"4186_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jad.2012.12.001","volume":"148","author":"S Leucht","year":"2013","unstructured":"Leucht S, Fennema H, Engel R, Kaspers-Janssen M, Lepping P, Szegedi A. What does the HAMD mean? J Affect Disord. 2013;148(2\u20133):243\u20138.","journal-title":"J Affect Disord"},{"issue":"3","key":"4186_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jad.2012.08.026","volume":"145","author":"R Boessen","year":"2013","unstructured":"Boessen R, Groenwold RH, Knol MJ, Grobbee DE, Roes KC. Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials. J Affect Disord. 2013;145(3):363\u20139.","journal-title":"J Affect Disord"},{"issue":"3","key":"4186_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/da.20271","volume":"25","author":"M Rynn","year":"2008","unstructured":"Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25(3):182\u20139.","journal-title":"Depress Anxiety"},{"key":"4186_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bbi.2017.01.021","volume":"62","author":"R Hou","year":"2017","unstructured":"Hou R, Garner M, Holmes C, Osmond C, Teeling J, Lau L, et al. Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. Brain Behav Immun. 2017;62:212\u20138.","journal-title":"Brain Behav Immun"},{"key":"4186_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2019.06.001","volume":"81","author":"R Hou","year":"2019","unstructured":"Hou R, Ye G, Liu Y, Chen X, Pan M, Zhu F, et al. Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. Brain Behav Immun. 2019;81:105\u201310.","journal-title":"Brain Behav Immun"},{"issue":"7","key":"4186_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.4088\/JCP.v67n0705","volume":"67","author":"S Bellino","year":"2006","unstructured":"Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry. 2006;67(7):1042\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"4186_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1078\/1433-187X-00309","volume":"10","author":"RJ Boerner","year":"2003","unstructured":"Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10(Suppl 4):38\u201349.","journal-title":"Phytomedicine"},{"issue":"2","key":"4186_CR17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","volume":"19","author":"B Bandelow","year":"2017","unstructured":"Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93\u2013107.","journal-title":"Dialogues Clin Neurosci"},{"issue":"10","key":"4186_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","volume":"19","author":"JR Strawn","year":"2018","unstructured":"Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057\u201370.","journal-title":"Expert Opin Pharmacother"},{"key":"4186_CR19","first-page":"CD006115","volume":"3","author":"CA Chessick","year":"2006","unstructured":"Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:CD006115.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4186-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:09:42Z","timestamp":1615680582000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4186-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4186"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4186-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"3 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Central ethical approval has been confirmed from the research ethics committee of Beijing Anding Hospital, Capital Medical University ((2017)63-201772FS-2). Local ethical approval from other participating hospitals has also been obtained. The study will be conducted in accordance with the principles of the Declaration of Helsinki. Trial organization, data management, monitoring, and reporting will also be conducted in accordance with the guidelines for Good Clinical Practice and other regulations. Patients will be given full and adequate oral and written information about the study. The consent will be provided by the patient or a legally authorized representative.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}